What is Integrated Micro-Chromatography Systems?
Integrated Micro-Chromatography Systems operates at the intersection of biotechnology and laboratory automation, providing critical infrastructure for clinical and research environments. The company is recognized for its proprietary IMCSzyme® line, which utilizes genetically modified beta-glucuronidase enzymes to improve precision in diagnostic testing. Furthermore, its patented IMCStips® technology facilitates automated solid-phase extraction, a cornerstone process in modern proteomics and metabolomics. By focusing on the intersection of glycobiology and high-throughput screening, the firm addresses the growing demand for affordable, scalable, and accurate laboratory tools that streamline complex biological research workflows.
How much funding has Integrated Micro-Chromatography Systems raised?
Integrated Micro-Chromatography Systems has raised a total of $801K across 2 funding rounds:
Debt
$350K
Debt
$451K
Debt (2020): $350K with participation from PPP
Debt (2021): $451K led by PPP
Key Investors in Integrated Micro-Chromatography Systems
PPP
Public-Private Partnership
What's next for Integrated Micro-Chromatography Systems?
With this major enterprise-level funding, Integrated Micro-Chromatography Systems is poised to scale its operational capacity and expand its footprint in the global genomics and proteomics markets. The strategic allocation of this capital will likely focus on enhancing R&D capabilities for next-generation extraction technologies and broadening the distribution of its enzymatic product portfolio. As the company transitions into this next phase of growth, it remains focused on maintaining high testing standards while driving innovation in laboratory efficiency, ultimately aiming to solidify its position as a key provider of essential tools for the life sciences industry.
See full Integrated Micro-Chromatography Systems company page
